Evidence map›Paper›PMID 42779256›Full record

ArticleRenal failure2026

The efficacy of

Min Min, Yazhen Yu, Changying Xing, Jiong Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Min MinNational Clinical Research Center of Kidney Diseases, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, China.
Yazhen YuNational Clinical Research Center of Kidney Diseases, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, China.
Changying XingDepartment of Nephrology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing Medical University, Nanjing, China.
Jiong ZhangNational Clinical Research Center of Kidney Diseases, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, China.ORCID 0000-0003-3402-0002

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemorrhagic fever with renal syndrome (HFRS) is frequently complicated by acute kidney injury (AKI). Although most patients recover from AKI with supportive care, some progress to chronic kidney disease (CKD). The incidence and determinants of CKD progression in patients with HFRS-AKI remain uncertain. Here, 99 patients with HFRS-AKI treated at Jinling Hospital were analyzed retrospectively to determine the rate of CKD progression and identify associated risk factors. Patients were divided into complete recovery (CR) and incomplete recovery (ICR) groups according to CKD progression. Baseline clinical and laboratory data were collected and analyzed. Overall, 27.3% of patients with HFRS-AKI progressed to CKD despite receiving supportive care. Facial flushing was more frequent in the ICR group than in the CR group (40.7% vs. 18.1%,

Indexed as

Acute Kidney InjuryCordycepsHemorrhagic Fever with Renal SyndromeRenal Insufficiency, ChronicAdultChinaDisease ProgressionEast Asian PeopleFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTreatment OutcomeAcute kidney injuryCordyceps sinensishemorrhagic fever with renal syndromeHFRSkidney outcomes

Identifiers

PMID42779256
PMCPMC13618102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.